American Association for Cancer Research
Browse

sorry, we can't preview this file

crc-22-0336-s06.docx (82.87 kB)

Fig. S6 from Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas

Download (82.87 kB)
journal contribution
posted on 2023-04-04, 02:00 authored by Xin Gao, Nermin Kady, Chenguang Wang, Suhaib Abdelrahman, Peter Gann, Maria Sverdlov, Ashley Wolfe, Noah Brown, John Reneau, Aaron M. Robida, Carlos Murga-Zamalloa, Ryan A. Wilcox

Fig. S6: GSEA in LAM

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

LAMs are a therapeutic vulnerability, as their depletion impairs T-cell lymphoma disease progression. Pacritinib, a dual CSF1R/JAK inhibitor, effectively impaired LAM viability and expansion, prolonged survival in preclinical T-cell lymphoma models, and is currently being investigated as a novel therapeutic approach in these lymphomas.